Loading...
•
Jun 30, 2024
UroGen Q2 2024 Earnings Report
UroGen reported Q2 2024 financial results and business highlights.
Key Takeaways
UroGen Pharma reported JELMYTO net product revenues of $21.8 million for Q2 2024 and ended the quarter with $241.3 million in cash, cash equivalents, and marketable securities. The company is focused on completing the NDA submission for UGN-102 and preparing for its potential approval and launch.
UGN-102 NDA submission is ahead of schedule with potential FDA decision in Q1 2025, assuming priority review.
UGN-102 Phase 3 ENVISION trial demonstrated 82.3% Duration of Response at 12 Months in LG-IR-NMIBC patients who achieved complete response at three months.
The company concluded Q2 2024 with $241.3 million in cash, cash equivalents, and marketable securities.
JELMYTO generated $21.8 million in net product revenues during Q2 2024.
UroGen
UroGen
UroGen Revenue by Segment
Revenue by Segment
JELMYTO Revenue
CapyFin.com Forward Guidance
UroGen anticipates JELMYTO revenue to be towards the lower end of the previously provided full-year 2024 guidance range and operating expenses to be towards the higher end of the guidance range. The company expects non-cash share-based compensation expense of $9 to $13 million and non-cash financing expense related to the prepaid obligation to RTW Investments to be in the range of $21 to $26 million for 2024. The cash component of the RTW obligation will be 13% of global net product sales of JELMYTO in 2024.